GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » PS Ratio

Extrawell Pharmaceutical Holdings (HKSE:00858) PS Ratio : 1.52 (As of May. 26, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Extrawell Pharmaceutical Holdings's share price is HK$0.038. Extrawell Pharmaceutical Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was HK$0.03. Hence, Extrawell Pharmaceutical Holdings's PS Ratio for today is 1.52.

The historical rank and industry rank for Extrawell Pharmaceutical Holdings's PS Ratio or its related term are showing as below:

HKSE:00858' s PS Ratio Range Over the Past 10 Years
Min: 1.23   Med: 5.07   Max: 12.04
Current: 1.52

During the past 13 years, Extrawell Pharmaceutical Holdings's highest PS Ratio was 12.04. The lowest was 1.23. And the median was 5.07.

HKSE:00858's PS Ratio is ranked better than
62.56% of 999 companies
in the Drug Manufacturers industry
Industry Median: 2.16 vs HKSE:00858: 1.52

Extrawell Pharmaceutical Holdings's Revenue per Sharefor the six months ended in Sep. 2023 was HK$0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was HK$0.03.

Warning Sign:

Extrawell Pharmaceutical Holdings Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Extrawell Pharmaceutical Holdings was 31.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -2.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was -3.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -10.00% per year.

During the past 13 years, Extrawell Pharmaceutical Holdings's highest 3-Year average Revenue per Share Growth Rate was 12.30% per year. The lowest was -21.60% per year. And the median was -7.20% per year.

Back to Basics: PS Ratio


Extrawell Pharmaceutical Holdings PS Ratio Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings PS Ratio Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.07 3.75 4.73 3.95 3.05

Extrawell Pharmaceutical Holdings Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.95 - 3.05 -

Competitive Comparison of Extrawell Pharmaceutical Holdings's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's PS Ratio distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's PS Ratio falls into.



Extrawell Pharmaceutical Holdings PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Extrawell Pharmaceutical Holdings's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.038/0.025
=1.52

Extrawell Pharmaceutical Holdings's Share Price of today is HK$0.038.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Extrawell Pharmaceutical Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was HK$0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Extrawell Pharmaceutical Holdings  (HKSE:00858) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Extrawell Pharmaceutical Holdings PS Ratio Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines